Pancreatic mass in a patient undergoing immunotherapy for metastatic renal cell carcinoma: dilemmas in management

Article Oncology

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

P. Heudel et al.

Summary: The use of ICIs for FPC appears to reduce the risk of developing SPC, while patients receiving CC or no ICIs/CC treatment for FPC have a higher incidence of SPC. Treatment with ICIs and/or CC for FPC is associated with a decreased risk of SPC in multivariate analysis.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma

C. N. Owen et al.

Summary: This study revealed that delayed irAEs occur in approximately 5.3% of patients receiving anti-PD-1-based therapy, with common manifestations including colitis, rash, and pneumonitis. Some patients may experience severe symptoms and even death as a result of delayed irAEs.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects

Enrico Munari et al.

Summary: Immune evasion is a crucial strategy adopted by tumor cells to promote survival and metastasis, with PD-1 playing a major role in inhibiting immune responses. Targeting the PD-1/PD-L1 axis has been a significant breakthrough in cancer treatment, representing unprecedented success in various cancer types. Further research on mechanisms regulating PD-1 expression and signaling in tumors is needed to improve therapeutic efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities

Stergios Boussios et al.

Summary: Immunotherapies hold great potential in cancer treatment, but severe adverse events limit their usage. Checkpoint inhibitors have shown promising clinical activity in hard to treat solid malignancies, but caution must be taken regarding potential risks and treatment strategies.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Oncology